Search results
Showing 16 to 30 of 110 results for ovarian cancer
This guideline covers care for people with a family history of breast, ovarian or another related (prostate or pancreatic) cancer. It aims to improve the long-term health of these families by describing strategies to reduce the risk of and promote early detection of breast cancer (including genetic testing and mammography). It also includes advice on treatments (tamoxifen, raloxifene) and surgery (mastectomy).
Evidence-based recommendations on niraparib (Zejula) for treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer in adults.
This guideline covers identifying children, young people and adults with symptoms that could be caused by cancer. It outlines appropriate investigations in primary care, and selection of people to refer for a specialist opinion. It aims to help people understand what to expect if they have symptoms that may suggest cancer.
Show all sections
Sections for NG12
- Overview
- Introduction
- Recommendations organised by site of cancer
- Recommendations on patient support, safety netting and the diagnostic process
- Recommended actions organised by symptom and findings of primary care investigations
- Terms used in this guideline
- Recommendations for research
- Rationale and impact
Tests in secondary care to identify people at high risk of ovarian cancer (HTG453)
Evidence-based recommendations on tests in secondary care to identify people at high risk of ovarian cancer. The tests are the IOTA ADNEX model, Overa (MIA2G), RMI I (at thresholds other than 250), ROMA and IOTA Simple Rules.
This guideline covers identifying and managing menopause, including in people with premature ovarian insufficiency. It aims to improve the consistency of support and information provided to people experiencing menopause.
Summary of the evidence on bevacizumab 7.5 mg/kg with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer..
NICE is unable to make a recommendation about the use in the NHS of bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer. This is because Roche did not provide an evidence submission.
Show all sections
Sections for TA560
Evidence-based recommendations on rucaparib (Rubraca) for the maintenance treatment of relapsed platinum-sensitive high-grade epithelial, ovarian, fallopian tube or primary peritoneal cancer that has completely or partially responded to platinum-based chemotherapy in adults.
Evidence-based recommendations on olaparib (Lynparza) for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy in adults.
In development Reference number: GID-TA11422 Expected publication date: 18 November 2026
NICE is unable to make a recommendation about the use in the NHS of bevacizumab for treating relapsed, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer. This is because Roche Products did not provide an evidence submission.
Show all sections
Sections for TA353
This guideline covers diagnosing and treating health-related fertility problems. It aims to reduce variation in practice and improve how fertility problems are investigated and managed.
Show all sections
Sections for NG257
- Overview
- Principles of care
- Initial advice to people concerned about delays in conception
- Advice about factors that can affect fertility
- Defining infertility and initial assessment
- Investigation of fertility problems and management strategies
- Management of male factor fertility problems
- Management of female factor fertility problems
This quality standard covers diagnosing and managing menopause in women, trans men and non-binary people registered female at birth, including those who have premature ovarian insufficiency (menopause before the age of 40, which can occur naturally or as a result of medical or surgical treatment). It describes high-quality care in priority areas for improvement.
View quality statements for QS143Show all sections
Sections for QS143
- Quality statements
- Quality statement 1: Diagnosing perimenopause and menopause
- Quality statement 2: Diagnosing premature ovarian insufficiency
- Quality statement 3: Managing premature ovarian insufficiency
- Quality statement 4: Reviewing treatments for menopause-associated symptoms
- Quality statement 5: Information before treatment likely to cause menopause
- Update information
- About this quality standard
This guideline covers care and support for people with advanced (stage 4) breast cancer. It aims to help them and their healthcare professionals make shared decisions about tests and treatments to improve outcomes and quality of life.
In development Reference number: GID-TA11774 Expected publication date: 30 September 2026